• Artemisinin, Nrf2, and Ferroptosis in Diabetic Cognition

  2026-08-15

  Wang et al. show that artemisinin improves learning and memory in STZ-induced T2DM mice while reducing hippocampal CA1 neuronal ferroptosis through Nrf2-associated antioxidant responses. Pharmacological blockade with ML385 and induction with erastin strengthen the study’s mechanistic conclusion and provide a useful framework for testing oxidative stress pathways in diabetic cognitive impairment.

• Cisplatin Assay Design: From DNA Damage to Response

  2026-08-14

  Cisplatin and CDDP are powerful tools for linking DNA crosslink formation to apoptosis, oxidative stress, and treatment response. This guide presents an assay-design framework that connects molecular endpoints with xenograft interpretation and clinical context.

• AZD8055: Practical mTOR Inhibition Guide

  2026-08-14

  AZD8055 (SKU A8214) is an ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer cell proliferation, and metabolism. This dossier-based guide covers stock preparation, assay design, QC, and troubleshooting; it should not be used to infer clinical efficacy or replace optimization in aqueous protocols.

• MDL 28170: A Selective Calpain Inhibitor Workflow

  2026-08-13

  MDL 28170 combines cell permeability, brain exposure, and nanomolar cysteine-protease inhibition for mechanistic neuroprotection research. This workflow connects calpain target engagement with BDNF/TrkB signaling, synaptic structure, apoptosis assays, and translational injury models.

• Phenothiazines, ROS, and Autophagy in Macrophage Defense

  2026-08-13

  The 2025 Frontiers in Immunology study shows that phenothiazines can strengthen macrophage antibacterial activity by coordinating lysosomal function, autophagy, and reactive oxygen species accumulation. Pharmacological inhibition of autophagy or ROS reduced this effect, while perphenazine improved infection-associated tissue outcomes in a Salmonella Typhimurium model, supporting phenothiazines as host-directed therapy leads rather than conventional antibiotics.

• SCH772984: Mapping ERK-Driven Tumor Resistance

  2026-08-12

  A translational framework for using SCH772984, a selective ERK1/2 inhibitor, to test whether MAPK signaling connects angiotensin II, HIF-1α-HILPDA biology, ferroptosis suppression, and radioresistance in nasopharyngeal carcinoma.

• In Vitro Drug Response Metrics in Cancer

  2026-08-12

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of cancer drug response. This framework helps researchers interpret anti-cancer assays more precisely, especially when cytostatic effects, cytotoxicity, and response timing may produce similar viability readouts.

• Hoechst 33258 as a Nuclear Readout of Tumor pH

  2026-08-11

  Hoechst 33258 is a bis-benzimide DNA stain that can strengthen tumor pH and lactate assays through reliable nuclear segmentation, cell counting, and phenotype tracking. This article explains how to use its signal as an assay anchor without confusing DNA fluorescence with a direct pH measurement.

• Lumiracoxib Workflows for COX-2 Research

  2026-08-11

  Lumiracoxib enables time-resolved interrogation of COX-2 signaling, from prostaglandin synthesis inhibition in cell assays to ischemia and revascularization studies in injured muscle. This practical guide translates recent venom-induced injury findings into assay design, dosing logic, controls, and troubleshooting steps.

• 3D Gold Nanocluster Arrays for Tunable SERS

  2026-08-10

  The reference study introduces a polymer pen lithography route for assembling highly ordered three-dimensional gold nanoparticle cluster arrays on patterned polyethylenimine scaffolds. The resulting SERS substrates combine a reported enhancement factor of 1.67 × 10^7 with intersubstrate reproducibility below 4.73% RSD, while allowing performance to be adjusted through lithographic pattern parameters.

• Pravastatin Sodium: A Transporter-Aware Assay Guide

  2026-08-09

  Pravastatin sodium is a selective HMG-CoA reductase inhibitor with value beyond LDL cholesterol reduction. This guide connects its cholesterol-biosynthesis mechanism with hepatocyte viability, OATP1B1 transport, and botanical-drug interaction assay design, highlighting how to interpret açaí safety data without overstating translational conclusions.

• Resiniferatoxin and TRPV1-Positive Afferent Silencing

  2026-08-08

  Szallasi’s 2023 review presents Resiniferatoxin (RTX) as a precision pharmacological tool that first activates and then selectively silences TRPV1-positive sensory afferents. Its analysis connects receptor pharmacology with intravesical, intra-articular, and neuraxial applications, while emphasizing the importance of route, exposure, reversibility, and translational safety.

• Ziprasidone Hydrochloride Assay Guide

  2026-08-07

  A scenario-based guide to using Ziprasidone Hydrochloride (SKU A5350) in cell viability, proliferation, cytotoxicity, and migration studies. It connects GOT1 inhibition data with practical stock preparation, concentration selection, interpretation, and vendor-reliability decisions.

• Boc-D-FMK: Driving Next-Gen Apoptosis and Inflammation Model

  2026-08-07

  This thought-leadership article unites mechanistic insight with translational foresight on Boc-D-FMK, a pan-caspase inhibitor, for apoptosis and inflammation research. It contextualizes Boc-D-FMK’s irreversible caspase inhibition, integration within current disease models, and its value in precision translational workflows. By connecting recent findings on gene-environment interactions, drug metabolism, and protocol optimization, this article provides strategic guidance beyond conventional product pages, supporting researchers seeking robust, reproducible, and clinically relevant outcomes.

• Testosterone Bounce as a Prognostic Marker in Degarelix-Trea

  2026-08-06

  The referenced study identifies 'testosterone bounce'—a transient rise in serum testosterone above 20 ng/dL following nadir—as a significant predictor of overall and cancer-specific survival in prostate cancer patients undergoing degarelix therapy. This finding suggests testosterone dynamics, not just absolute suppression, have prognostic value beyond PSA levels in hormone-treated prostate cancer.

11731 records 1/783 page Next 12345 下5页 Last page